EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 165 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR How People With Cancer Can Benefit From Online Therapy October 22, 2020 3 Things to Reduce Stress During Cancer Treatment: A Patient’s Perspective January 30, 2024 Breast Cancer Patient Given 2 Years to Live is Now a... May 28, 2021 Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens... March 26, 2025 Load more HOT NEWS Dr Ian Walker on Smoking: ‘An unequal burden, but a fixable... Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults EMA Recommends Granting a Marketing Authorisation for Tisotumab Vedotin Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has...
